Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Biosciences Withdraws IPO, Citing Amersham Acquisition

NEW YORK, April 24 - Amersham Biosciences, which filed for an initial public offering as APBiotech in October 2000, withdrew its offering from the SEC yesterday, citing the company's recent acquisition by Amersham. In February last year, after several delays, the company had set a price of $15-$17 per share for 18,200,000 shares of common stock and said it would use the cash for "general corporate purposes, primarily to fund our operations and to pay indebtedness."


In March Amersham said it planned to buy Pharmacia's 45 percent stake in Amersham Biosciences for £704 million, or roughly $992 million.


 At the time of its filing, Amersham listed as its competitors: PE Biosystems, Packard BioScience, Affymetrix, the 
 Micromass division of Waters, Aurora Biosciences, and Third Wave Technologies. 
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.